↓ Skip to main content

Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?

Overview of attention for article published in Journal of Translational Medicine, October 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#18 of 2,141)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
15 news outlets
twitter
5 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?
Published in
Journal of Translational Medicine, October 2015
DOI 10.1186/s12967-015-0688-5
Pubmed ID
Authors

Samuel C. Wagner, Thomas E. Ichim, Hong Ma, Julia Szymanski, Jesus A. Perez, Javier Lopez, Vladimir Bogin, Amit N. Patel, Francisco M. Marincola, Santosh Kesari

Abstract

Angiogenesis is essential for the growth and metastasis of solid tumors. The tumor endothelium exists in a state of chronic activation and proliferation, fueled by the tumor milieu where angiogenic mediators are aberrantly over-expressed. Uncontrolled tumor growth, immune evasion, and therapeutic resistance are all driven by the dysregulated and constitutive angiogenesis occurring in the vasculature. Accordingly, great efforts have been dedicated toward identifying molecular signatures of this pathological angiogenesis in order to devise selective tumor endothelium targeting therapies while minimizing potential autoimmunity against physiologically normal endothelium. Vaccination with angiogenic antigens to generate cellular and/or humoral immunity against the tumor endothelium has proven to be a promising strategy for inhibiting or normalizing tumor angiogenesis and reducing cancer growth. Here we review tumor endothelium vaccines developed to date including active immunization strategies using specific tumor endothelium-associated antigens and whole endothelial cell-based vaccines designed to elicit immune responses against diverse target antigens. Among the novel therapeutic options, we describe a placenta-derived endothelial cell vaccine, ValloVax™, a polyvalent vaccine that is antigenically similar to proliferating tumor endothelium and is supported by pre-clinical studies to be safe and efficacious against several tumor types.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 4%
Unknown 26 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 26%
Researcher 4 15%
Student > Bachelor 3 11%
Student > Doctoral Student 3 11%
Student > Ph. D. Student 3 11%
Other 5 19%
Unknown 2 7%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 26%
Agricultural and Biological Sciences 7 26%
Medicine and Dentistry 5 19%
Immunology and Microbiology 3 11%
Psychology 1 4%
Other 3 11%
Unknown 1 4%

Attention Score in Context

This research output has an Altmetric Attention Score of 119. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 May 2017.
All research outputs
#88,222
of 9,763,361 outputs
Outputs from Journal of Translational Medicine
#18
of 2,141 outputs
Outputs of similar age
#3,737
of 248,750 outputs
Outputs of similar age from Journal of Translational Medicine
#2
of 89 outputs
Altmetric has tracked 9,763,361 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,141 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,750 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.